Gene: C19orf47

126526
-
chromosome 19 open reading frame 47
protein-coding
19q13.2
Ensembl:ENSG00000160392 Vega:OTTHUMG00000179028 UniprotKB:Q8N9M1
NC_000019.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.004e-1 (AD)  5.266e-2 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7247916chr19:40310623 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZBTB470.788
MAP2K70.785
ASPHD10.779
TRIM410.777
CLIP20.757
VASH10.749
RILPL10.749
C22orf460.733
SH3PXD2A0.732
PEX50.729

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.571
OR4F5-0.519
CP-0.308
C1orf141-0.272
TNFRSF11B-0.268
GJB2-0.258
ADH1B-0.258
TTLL10-AS1-0.258
DPEP3-0.258
HBD-0.248

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF47 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF47 mRNA"27188386
D001280AtrazineAtrazine results in increased expression of C19ORF47 mRNA25929836
D001280AtrazineAtrazine results in increased expression of C19ORF47 mRNA22378314
C006780bisphenol Abisphenol A results in decreased expression of C19ORF47 mRNA25181051
C000944dicrotophosdicrotophos results in increased expression of C19ORF47 mRNA28302478
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF47 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of C19ORF47 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0005654nucleoplasm-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal